Perrigo Company plc Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Tax
Perrigo Company plc (PRGO) reported Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Tax of -$1.10 million for the 3-month period ending 2014-09-27, per its 8-K filed 2014-11-20.
Discontinued › Expense Statement › Income Tax
us-gaap:OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesTax · last filed 2014-11-20
- Perrigo Company plc other comprehensive income (loss), derivatives qualifying as hedges, tax for the quarter ending 2014-09-27 was -$1.10M.
- Perrigo Company plc other comprehensive income (loss), derivatives qualifying as hedges, tax for the quarter ending 2013-09-28 was -$4.60M.
- Perrigo Company plc other comprehensive income (loss), derivatives qualifying as hedges, tax for fiscal 2014 was -$1.20M, a 137.50% decline from fiscal 2013.
- Perrigo Company plc other comprehensive income (loss), derivatives qualifying as hedges, tax for fiscal 2013 was $3.20M, a 37.25% decline from fiscal 2012.
- Perrigo Company plc other comprehensive income (loss), derivatives qualifying as hedges, tax for fiscal 2012 was $5.10M.
| Period end | Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Tax 3 month | Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Tax 12 month |
|---|---|---|
| 2014-09-27 | -$1.10M 8-K · filed 2014-11-20 | |
| 2014-06-28 | -$1.20M 10-K · filed 2014-08-14 | |
| 2013-09-28 | -$4.60M 8-K · filed 2014-11-20 | |
| 2013-06-29 | $3.20M 10-K · filed 2014-08-14 | |
| 2012-06-30 | $5.10M 10-K · filed 2014-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |